Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 6,500 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Edwards Lifesciences Trading Up 0.3 %

NYSE EW opened at $76.23 on Friday. The business’s 50-day moving average price is $72.67 and its two-hundred day moving average price is $69.50. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $44.96 billion, a PE ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. boosted its position in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its position in shares of Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $3,702,000. Finally, Avanza Fonder AB bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $4,845,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday. Truist Financial reiterated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Piper Sandler upped their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.